Nogueira Raul G, Etter Katherine, Nguyen Thanh N, Ikeme Shelly, Wong Charlene, Frankel Michael, Haussen Diogo C, Del Rio Carlos, McDaniel Michael, Sachdeva Rajesh, Devireddy Chandan M, Al-Bayati Alhamza R, Mohammaden Mahmoud H, Doheim Mohamed F, Pinheiro Agostinho C, Liberato Bernardo, Jillella Dinesh V, Bhatt Nirav R, Khanna Rahul
Department of Neurology, UPMC Stroke Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Global Provider and Payer Value Demonstration, Health Economics and Market Access, Johnson & Johnson, Raynham, MA, USA.
BMJ Med. 2023 May 11;2(1):e000207. doi: 10.1136/bmjmed-2022-000207. eCollection 2023.
To measure the impact of the covid-19 pandemic on admissions to hospital and interventions for acute ischemic stroke and acute myocardial infarction.
A retrospective analysis.
746 qualifying hospitals in the USA from the Premier Healthcare Database.
Patients aged 18 years and older who were admitted to hospital with a primary diagnosis of acute ischemic stroke or acute myocardial infarction between 1 March 2019 and 28 February 2021.
Relative changes in volumes were assessed for acute ischemic stroke and acute myocardial infarction hospital admissions as well as intravenous thrombolysis, mechanical thrombectomy, and percutaneous coronary intervention (overall and for acute myocardial infarction only) across the first year of the pandemic versus the prior year. Mortality in hospital and length of stay in hospital were also compared across the first year of the pandemic versus the corresponding period the year prior. These metrics were explored across the different pandemic waves.
Among 746 qualifying hospitals, admissions to hospital were significantly reduced after the covid-19 pandemic compared with before the pandemic for acute ischemic stroke (-13.59% (95% confidence interval-13.77% to -13.41%) and acute myocardial infarction (-17.20% (-17.39% to -17.01%)), as well as intravenous thrombolysis (-9.47% (-9.99% to -9.02%)), any percutaneous coronary intervention (-17.89% (-18.06% to -17.71%)), and percutaneous coronary intervention for acute myocardial infarction (-14.36% (-14.59% to -14.12%)). During the first year of the pandemic versus the previous year, the odds of mortality in hospital for acute ischemic stroke were 9.00% higher (3.51% 3.16%; ratio of the means 1.09 (95% confidence interval (1.03 to 1.15); P=0.0013) and for acute myocardial infarction were 18.00% higher (4.81% 4.29%; ratio of the means 1.18 (1.13 to 1.23); P<0.0001).
We observed substantial decreases in admissions to hospital with acute ischemic stroke and acute myocardial infarction, but an increase in mortality in hospital throughout the first year of the pandemic. Public health interventions are needed to prevent these reductions in future pandemics.
评估新冠疫情对急性缺血性卒中及急性心肌梗死住院率和干预措施的影响。
一项回顾性分析。
来自美国Premier医疗数据库中的746家符合条件的医院。
2019年3月1日至2021年2月28日期间,因急性缺血性卒中或急性心肌梗死入院的18岁及以上患者。
评估疫情第一年与前一年相比,急性缺血性卒中和急性心肌梗死住院量的相对变化,以及静脉溶栓、机械取栓和经皮冠状动脉介入治疗(总体以及仅针对急性心肌梗死)的情况。还比较了疫情第一年与前一年同期的住院死亡率和住院时间。这些指标在不同的疫情波次中进行了探讨。
在746家符合条件的医院中,与疫情前相比,新冠疫情后急性缺血性卒中的住院率显著降低(-13.59%(95%置信区间-13.77%至-13.41%)),急性心肌梗死的住院率也显著降低(-17.20%(-17.39%至-17.01%)),静脉溶栓率降低(-9.47%(-9.99%至-9.02%)),任何经皮冠状动脉介入治疗率降低(-17.89%(-18.06%至-17.71%)),急性心肌梗死的经皮冠状动脉介入治疗率降低(-14.36%(-14.59%至-14.12%))。与前一年相比,疫情第一年急性缺血性卒中的住院死亡率高出9.00%(3.51%对3.16%;均值比1.09(95%置信区间(1.03至1.15);P = 0.0013),急性心肌梗死的住院死亡率高出18.00%(4.81%对4.29%;均值比1.18(1.13至1.23);P < 0.0001)。
我们观察到急性缺血性卒中和急性心肌梗死的住院率大幅下降,但在疫情的第一年住院死亡率有所上升。需要采取公共卫生干预措施以防止未来疫情中出现这些下降情况。